ATE516041T1 - Synergistische zusammensetzungen mit fk-228 - Google Patents

Synergistische zusammensetzungen mit fk-228

Info

Publication number
ATE516041T1
ATE516041T1 AT05719967T AT05719967T ATE516041T1 AT E516041 T1 ATE516041 T1 AT E516041T1 AT 05719967 T AT05719967 T AT 05719967T AT 05719967 T AT05719967 T AT 05719967T AT E516041 T1 ATE516041 T1 AT E516041T1
Authority
AT
Austria
Prior art keywords
antitumor agent
antitumor
synergistic compositions
agent
dna
Prior art date
Application number
AT05719967T
Other languages
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE516041T1 publication Critical patent/ATE516041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05719967T 2004-02-25 2005-02-25 Synergistische zusammensetzungen mit fk-228 ATE516041T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29
PCT/JP2005/003689 WO2005079827A2 (en) 2004-02-25 2005-02-25 Antitumor agent

Publications (1)

Publication Number Publication Date
ATE516041T1 true ATE516041T1 (de) 2011-07-15

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05719967T ATE516041T1 (de) 2004-02-25 2005-02-25 Synergistische zusammensetzungen mit fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (de)
EP (1) EP1718322B1 (de)
JP (1) JP4930055B2 (de)
AT (1) ATE516041T1 (de)
CA (1) CA2557540A1 (de)
CY (1) CY1111926T1 (de)
DK (1) DK1718322T3 (de)
PL (1) PL1718322T3 (de)
PT (1) PT1718322E (de)
SI (1) SI1718322T1 (de)
WO (1) WO2005079827A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210794B1 (pl) * 2001-08-21 2012-03-30 Astellas Pharma Inc Zastosowanie inhibitora deacetylazy histonowej FK228 lub jego soli
MXPA04009761A (es) * 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
JPWO2004074478A1 (ja) * 2003-02-19 2006-06-01 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
EP1965824A4 (de) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc Metaboliten-derivate des hdac-inhibitors fk228
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
CN101801994A (zh) * 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
WO2010036404A2 (en) * 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
EP2366398A1 (de) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Krebstherapie mit einem Parvovirus in Kombination mit einem HDAC-Hemmer
WO2011156119A1 (en) * 2010-06-07 2011-12-15 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
US20120190817A2 (en) 2010-07-12 2012-07-26 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
WO1999022773A2 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
CA2393682C (en) * 1999-12-08 2012-01-31 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
JP4810784B2 (ja) 2000-07-17 2011-11-09 アステラス製薬株式会社 還元型ｆｋ２２８およびその用途
WO2002020817A1 (en) 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
CA2432797C (en) * 2000-12-18 2014-02-04 David J. Yang Local regional chemotherapy and radiotherapy using in situ hydrogel
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
PL210794B1 (pl) 2001-08-21 2012-03-30 Astellas Pharma Inc Zastosowanie inhibitora deacetylazy histonowej FK228 lub jego soli
PL368035A1 (en) * 2001-08-31 2005-03-21 Bristol-Myers Squibb Company Compositions and methods for the treatment of cancer
EP1293205A1 (de) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
MXPA04009761A (es) 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
JPWO2004074478A1 (ja) 2003-02-19 2006-06-01 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
EP2238982B8 (de) 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapiemittel für Weichgewebesarkom
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent

Also Published As

Publication number Publication date
EP1718322B1 (de) 2011-07-13
US20050187149A1 (en) 2005-08-25
US7951780B2 (en) 2011-05-31
WO2005079827A2 (en) 2005-09-01
JP4930055B2 (ja) 2012-05-09
CA2557540A1 (en) 2005-09-01
JP2007524650A (ja) 2007-08-30
SI1718322T1 (sl) 2011-09-30
DK1718322T3 (da) 2011-08-29
WO2005079827A3 (en) 2005-12-08
PL1718322T3 (pl) 2011-12-30
PT1718322E (pt) 2011-09-05
US20110160295A1 (en) 2011-06-30
EP1718322A2 (de) 2006-11-08
US8822422B2 (en) 2014-09-02
CY1111926T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
ATE516041T1 (de) Synergistische zusammensetzungen mit fk-228
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007103510A3 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
UA96592C2 (uk) Індолопіридини як модулятори кінезину eg5
WO2007054573A3 (en) Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
BRPI0719250A2 (pt) Métodos e composições com opalescência reduzida.
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
ATE510822T1 (de) Kaliumkanalinhibitoren
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
MY142792A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
ATE426409T1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
WO2009047434A3 (fr) Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant
GT200400113A (es) Productos aril-heteroaromaticos, composiciones que los contienen y su utilizacion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1718322

Country of ref document: EP